Are we trumping bone disease in prostate cancer?

Oncology

Volumn 25, Issue 14, 2011, Pages

  Slovin, Susan F ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; ANDROGEN RECEPTOR; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; DOCETAXEL; ENDOTHELIN 1; LEXIDRONAM SAMARIUM SM 153; LIPOCORTIN 2; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; RADIUM 223; SAMARIUM 153; SCATTER FACTOR RECEPTOR; STROMAL CELL DERIVED FACTOR 1; STRONTIUM 89; UNCLASSIFIED DRUG; UROKINASE;

ANALGESIA; ARTICLE; BONE DISEASE; BONE METASTASIS; BONE TURNOVER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PAIN; CANCER STAGING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; NONHUMAN; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; BONE TUMOR; MALE; METASTASIS; NOTE; PATHOLOGY; PROSTATE TUMOR;

BONE NEOPLASMS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84855583574     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Scher HI, Halaby S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;267:1148-59.
2. Roodman GD. Role of stromal-derived cytokines and growth factors in bone metastasis. Cancer. 2003;97(3 Suppl):733-8.
3. Christopher MJ, Liu F, Hilton MJ, et al. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood. 2009;114:1283-4.
4. Shiozawa Y, Havens AM, Jung Y, et al. Annexin II/annexinII receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem. 2008;105:370-80.
5. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature. 2006;440:692-6.
6. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene. 2004;341:19-39.
7. Hall CL, Bafico A, Dai J, et al. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res. 2005;65:7554-60.
8. Hall CL, Daignault SD, Shah RB, et al. Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis. Prostate. 2008;68:1396-404.
9. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944-9.
10. Fizazi K, Lipton A, Mariette X, et al. A randomized phase 2 trial of denosumab in patients with bone metastases from prostate, breast cancer or other neoplasms after IV bisphosphonates. J Clin Oncol. 2009;27:1564-71.
11. Lipton A. Future treatment of bone metastases. Clin Cancer Res. 2006;12(20Pt2):6305s-6308s.
12. McClung M, Bone H, Cosman F, et al. A randomized, double-blind, placebo-controlled study of odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24 month results. Presented at the 30th annual meeting of the American Society for Bone and Mineral Research, Montreal, Quebec, Sept 12-16, 2008 (abstr 1291).
13. Odero-Marah VA, Wang R, Chu G, et al. Receptor activator of NF-kappaB ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells. Cell Res. 2008;18:858-70.
14. Armstrong AP, Miller RE, Jones JC, et al. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes. Prostate. 2008;68:92-104.
15. Morris MJ, Pandit-Taska N, Carrasquillo J, et al. Phase I study of samarium-153 Lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27:2436-42.
16. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27:2429-35.
17. Bankhead C. Radium-223 improves prostate cancer survival. Medpage Today. 2011. Available at: http://www.medpagetoday.com/MeetingCoverage/ECCO-ESMO/28706. Accessed October 2, 2011.
18. Clinical Trial NCT00699751: Phase III study of Alpharadin (radium-223) in patients with symptomatic hormone refractory prostate cancer with skeletal metastases. US National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/show/NCT00699751. Accessed November 6, 2011.